Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.5052W HIGH $16.99
Volume
10.38 K
Value Traded
4.05 M
Short % Float
6.23%
-0.99%Week
+1.01%1 Month
-22.61%3 Month
-27.3%6 Month
-73.94%5 Year
-6.52%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
369.44 M
EPS (TTM)
-1.52
P/E Ratio
-
Ent. Value
484.37 M
Total Shares
40.73 M
Float Shares
40.24 M
Insiders
1.21%
Institutions
95.12%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
OFIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Orthofix Medical Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Orthofix Medical Inc.
5Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 4
▲Reimbursement / PricingPost-Market
Medicare reimbursement for non-invasive bone growth stimulators restored to prior level
bone growth stimulatorssource ↗
▼Legal / SettlementCorporate
Arbitration award and settlement payments to three former executives
▲Runway Guidance UpdateCorporate
Orthofix raises full-year 2026 net sales and adjusted EBITDA guidance
Past FDA Catalysts and PDUFA Decisions
How OFIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Orthofix Medical Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every OFIX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fisher PatrickOfficer (President, Global Limb Recon) | Sell | -150 50,919 held | $9.44 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in OFIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.2 % (-71.4 %) | 2.91 M | 261.15 K | -56.61% ( -340.78 K) |
OFIX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OFIX ranks across every disease it competes in
Competitive Position is a premium feature
See how OFIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOFIX News
OFIX▼ -14.6%on this news
Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
Orthofix Medical Inc. announced its financial results for the second quarter of 2026, showcasing significant operational progress. The company has raised its guidance for net sales and adjusted EBITDA for the full year, reflecting a positive outlook. The results exclude the impact of discontinued product lines, emphasizing the company's focus on core operations.
Read more →OFIXOrthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. has announced its participation in two upcoming investor conferences. The Needham Virtual MedTech & Diagnostics 1x1 Conference will take place on August 10, 2026, followed by the Canaccord Genuity’s 46th Annual Growth Conference in Boston on August 12, 2026. These events will allow the company to engage with investors and discuss its growth prospects.
Read more →OFIXOrthofix to Report Second Quarter 2026 Financial Results
Orthofix Medical Inc. has announced the release date for its second quarter 2026 financial results, which will be available on August 5, 2026. The company will conduct a conference call at 8:30 am Eastern Time to discuss the results. This event highlights the company's commitment to keeping investors informed.
Read more →OFIXOrthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting
Orthofix Medical Inc. has announced new innovations in pediatric limb reconstruction, aimed at enhancing treatment options for pediatric and small stature patients. These advancements will be showcased at the upcoming Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting in Orlando, Florida. The event is scheduled for May 6-8, 2026.
Read more →OFIXOrthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
Orthofix has reported its first quarter results for 2026, emphasizing steady execution in its operations, particularly following actions taken in the spine commercial channel. The company has reaffirmed its financial guidance for the full year of 2026, indicating confidence in its performance. Further details on the financial outcomes were not disclosed in the article.
Read more →OFIXOrthofix to Report First Quarter 2026 Financial Results
Orthofix Medical Inc. will announce its first quarter 2026 financial results on May 5, 2026, before market opening. A conference call and webcast will follow at 8:30 am Eastern Time. Interested parties can join the call using the provided access numbers. The company emphasizes its dedication to improving patient outcomes through innovative medical technologies.
Read more →OFIXOrthofix Realigns Spine Leadership to Strengthen Focus and Execution
Orthofix Medical Inc. has announced a strategic realignment of its Spine leadership team to enhance decision-making and accelerate growth. The company reported preliminary net sales of approximately $196.7 million for Q1 2026, reflecting a modest increase compared to the previous year. The leadership changes are aimed at improving commercialization and operational synergies across its product portfolio.
Read more →OFIXOrthofix Realigns Spine Leadership to Strengthen Focus and Execution Company Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 Outlook
Orthofix Medical Inc. has announced a strategic realignment of its Spine leadership team to enhance focus and execution in its core business. The company reported preliminary net sales of approximately $196.7 million for the first quarter of 2026, which marks a 1.6% increase over the previous year. Orthofix reaffirmed its full-year 2026 guidance, anticipating net sales between $850 million to $860 million. This growth strategy aims to leverage operational synergies and expand high-value opportunities in the Spine segment, while addressing changes in their leadership structure to facilitate faster decision-making.
Read more →OFIX▼ -6.2%on this news
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
Orthofix Medical Inc. reported its financial results for Q4 and full-year 2025, showing a net sales increase and strong performance in key segments. The company provided optimistic guidance for 2026, focusing on expanding market penetration and enhancing commercial execution. Despite a reported net loss, adjusted EBITDA showed growth, indicating operational progress.
Read more →OFIXOrthofix to Report Fourth Quarter and Full-Year 2025 Financial Results
Orthofix Medical Inc. will announce its fourth quarter and full-year 2025 financial results on February 24, 2026. A conference call will be held at 8:30 am ET to discuss these results. Investors can access the call through provided phone numbers and a webcast. The company emphasizes its commitment to keeping investors informed through its website.
Read more →OFIX▼ -7.4%on this news
Orthofix Reports Third Quarter 2025 Financial Results LEWISVILLE, Texas —
Orthofix Medical Inc. reported its financial results for the third quarter of 2025, showcasing a notable increase in net sales despite a net loss. The company experienced a 5% rise in net sales compared to the previous year, driven primarily by growth in the U.S. Spine Fixation and Orthopedics segments. Additionally, Orthofix has narrowed its full-year sales guidance while raising the low end of its adjusted EBITDA guidance. Although the decision to discontinue the M6 product lines has introduced some challenges, the company has demonstrated solid operational performance and positive cash flow.
Read more →OFIX▲ +13.5%on this news
Orthofix Reports Second Quarter 2025 Financial Results LEWISVILLE, Texas —
Orthofix Medical Inc. reported its financial results for Q2 2025, indicating a 2.3% increase in net sales compared to the previous year. The company achieved positive adjusted EBITDA of $20.6 million and positive free cash flow of $4.5 million, despite a net loss of $14.1 million. Orthofix reaffirmed full-year guidance for net sales and adjusted EBITDA, while also highlighting challenges from the discontinued M6 product lines. New product launches are expected to enhance growth and patient outcomes moving forward.
Read more →OFIX▼ -10.9%on this news
Orthofix Reports First Quarter 2025 Financial Results
Orthofix Medical Inc. has reported its financial results for Q1 2025, showing a year-over-year increase in net sales by 2.7% to $193.6 million. The company reaffirmed its full-year guidance for adjusted EBITDA and free cash flow, despite reporting a net loss of $(53.1) million. Key highlights include significant growth in the Bone Growth Therapies segment and the recent clearance of the TrueLok Elevate TBT System. While the company acknowledged some softness in specific segments due to optimization efforts, it expressed confidence in future growth based on strategic priorities.
Read more →OFIXOrthofix Announces Appointment of Vickie Capps to Board of Directors
Orthofix Medical Inc. announced the appointment of Vickie Capps to its Board of Directors, effective March 11, 2025. Capps brings significant experience in global business operations and corporate finance, which is deemed valuable at this pivotal stage in the company's strategic transformation. This change expands Orthofix's Board to ten members, comprising professionals with diverse backgrounds in healthcare and business. Capps expressed enthusiasm about contributing to the company's mission of delivering innovative medical technologies.
Read more →OFIXOrthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
Orthofix Medical Inc. reported strong financial results for the fourth quarter and full-year 2024, highlighting record net sales driven by growth in spine and orthopedic products. Despite a net loss of $(29.1) million in the fourth quarter, the company's adjusted EBITDA saw a significant increase, indicating improved operational efficiency. The company also announced its financial guidance for 2025, projecting net sales between $818 million and $826 million, factoring in the discontinuation of its M6 artificial disc lines to focus on more profitable areas. Overall, Orthofix enters 2025 with positive momentum and adjusted growth targets.
Read more →About Orthofix Medical Inc.
Headquarters3451 PLANO PARKWAY, LEWISVILLE, TX, 75056
BIOPHARMAWATCH ELITE PLUS
Trade the next OFIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime